What was recalled
This page synthesizes the quercetin inclusion framework in commercial pet food and pet supplements. Quercetin is a polyphenolic compound in the flavonoid family, specifically the flavonol subclass. The molecule has a characteristic three-ring polyphenol structure with five hydroxyl substituents (at positions 3, 3’, 4’, 5, and 7 on the flavonoid backbone) that confer the antioxidant and bioactive properties. Quercetin occurs in human and pet diets primarily as quercetin glycosides — the aglycone bound to a sugar moiety through a glycosidic bond. Common quercetin glycosides include rutin (quercetin-3-O-rutinoside, found prominently in buckwheat, citrus, and many vegetables), isoquercitrin (quercetin-3-O-glucoside), quercitrin (quercetin-3-O-rhamnoside), and hyperoside (quercetin-3-O-galactoside). Each glycoside has a different bioavailability profile because the sugar moiety affects intestinal absorption and intestinal-bacterial deconjugation kinetics.
The pharmacology of quercetin has been studied extensively for several mechanism classes. Antioxidant activity operates through direct radical scavenging (the polyphenol structure donates hydrogen atoms to neutralize reactive oxygen species) plus indirect mechanisms (Nrf2 antioxidant response element activation, which upregulates cellular antioxidant defense genes including heme oxygenase-1, glutathione peroxidase, and NAD(P)H quinone oxidoreductase). Mast cell stabilization is the mechanism most directly tied to quercetin marketing positioning in pet allergy support — cell-culture and rodent studies document quercetin-mediated inhibition of histamine release from mast cells through calcium-flux modulation and protein kinase C inhibition. Anti-inflammatory effect operates through NF-kB pathway inhibition similar to curcumin and other polyphenols. Cardiovascular effects are documented in human observational and small intervention studies but not consistently in controlled trials.
Commercial pet quercetin inclusion has emerged primarily in pet supplements rather than main-meal pet food. Supplement formulations for canine allergy support typically deliver 50-500 mg quercetin daily for medium-size dogs, sometimes co-formulated with bromelain (covered separately on our bromelain enzyme page), vitamin C, and other bioactives. Main-meal pet food quercetin inclusion is less common but appears in some boutique formulations marketed for skin, joint, or immune support positioning, typically at much lower inclusion rates than supplement formulations. The oral bioavailability of free quercetin is approximately 2-5%, with extensive intestinal and hepatic conjugation producing quercetin glucuronide and sulfate metabolites that are rapidly cleared in urine. Quercetin glycosides from natural plant sources have variable bioavailability depending on the sugar moiety and the host’s intestinal-bacterial deconjugation activity. Bioavailability-enhanced formulations include quercetin phytosome with phosphatidylcholine (similar formulation strategy to Meriva curcumin phytosome) and EMIQ (enzymatically modified isoquercitrin), a quercetin glucoside with attached alpha-glucose chains that improve aqueous solubility and intestinal absorption.
Why it was recalled
The structural marketing-evidence-gap concern has three layers. Layer one — bioavailability limit at typical pet supplement and pet food inclusion: free quercetin oral bioavailability is approximately 2-5%, similar to but somewhat higher than curcumin. Pet supplement quercetin inclusion at 50-500 mg daily delivers absorbed quercetin doses of approximately 1-25 mg daily for medium-size dogs, with conjugated metabolites at higher levels. Pet food quercetin inclusion at typical rates is substantially lower and delivers absorbed quercetin doses on the order of 0.1-1 mg daily. Therapeutic plasma quercetin concentrations in human controlled trials typically require 500-1000 mg daily oral quercetin with food, often delivering plasma concentrations of 100-500 nanomolar, which is below the in vitro mast cell stabilization threshold (typically 10-50 micromolar). The implication is that translating in vitro mast cell stabilization mechanism to clinical canine allergy benefit at oral quercetin doses requires either substantially higher absolute doses than typical supplementation, or bioavailability-enhanced formulations.
Layer two — companion-animal controlled-trial evidence is limited: the canine and feline controlled-trial literature on therapeutic quercetin supplementation is sparse. A few small canine studies have evaluated quercetin or quercetin combination formulations for atopic dermatitis with mixed results; veterinary clinical use for allergy support exists at the level of complementary-medicine practice rather than evidence-supported guideline. The translation from in vitro mast cell stabilization and human cardiovascular epidemiology to companion-animal therapeutic recommendation requires more controlled-trial work. Brands marketing quercetin inclusion for canine allergy support are operating ahead of the companion-animal evidence base, with mechanistic plausibility but limited direct clinical demonstration.
Layer three — drug-interaction and dosing concerns at higher doses: high-dose quercetin supplementation can produce modest cytochrome P450 enzyme inhibition (relevant for pets on chronic medications with hepatic metabolism), modest antiplatelet effect, and rare hepatotoxicity at very high doses (typically reported only in unusual supplementation patterns). At typical pet supplement and pet food inclusion rates, none of these reaches clinically significant magnitude. Pet owners using pharmacologic-dose quercetin supplementation outside veterinary direction should be aware of these concerns particularly in pets on cyclosporine, oclacitinib (Apoquel), and other immunomodulatory or hepatically metabolized medications used in canine allergy management.
Health risks for your pet
Quercetin at typical pet food and pet supplement inclusion rates is generally well-tolerated and safe for dogs and cats. The mechanistic concerns relevant at higher doses include modest CYP450 inhibition (relevant for pets on cyclosporine, oclacitinib, and other immunomodulatory or hepatically metabolized canine allergy medications), modest antiplatelet effect (relevant for pets on anticoagulant therapy or scheduled for surgical procedures), rare hepatotoxicity at very high doses, and theoretical pro-oxidant effect at high doses through catechol-quinone redox cycling (the mechanism is well-established in vitro and at very high doses but is not typically observed at supplementation doses). At typical pet inclusion rates, these concerns rarely reach clinically significant magnitude.
The drug-interaction concern is particularly relevant in canine atopic dermatitis management, where pets often receive cyclosporine, oclacitinib (Apoquel), corticosteroids, and other immunomodulatory medications. Pet owners adding pharmacologic-dose quercetin supplementation to these regimens warrant veterinary discussion to avoid unintended drug-interaction effects. Coordinated veterinary management of atopic dermatitis typically integrates pharmaceutical and adjunctive interventions rather than relying on supplementation alone.
What to do if you bought affected product
Pet owners can interpret quercetin pet food and supplement inclusion appropriately through several practical approaches: (1) treat quercetin as an adjunctive option, not a primary therapeutic intervention — the mast cell stabilization mechanism is plausible but the bioavailability limit and companion-animal trial-evidence gap mean that pet food and supplement quercetin inclusion is unlikely to produce measurable allergy benefit comparable to pharmaceutical interventions; (2) for diagnosed canine atopic dermatitis, work with your veterinarian on first-line pharmaceutical interventions (oclacitinib, cyclosporine, allergen-specific immunotherapy, corticosteroids in selected cases) rather than relying on dietary quercetin inclusion as primary therapy; (3) if pursuing pharmacologic-dose quercetin supplementation under veterinary guidance, choose bioavailability-enhanced formulations (quercetin phytosome, EMIQ) over free quercetin to achieve therapeutic plasma concentrations at reasonable absolute doses; the bioequivalence calculations matter for therapeutic translation; (4) watch for drug interactions particularly with cyclosporine, oclacitinib, and other CYP450-metabolized canine allergy medications; coordinate any pharmacologic-dose supplementation with the prescribing veterinarian; (5) do not assume quercetin pet food inclusion replaces atopic dermatitis pharmaceutical therapy — the mast cell stabilization mechanism is one of multiple mediators in atopic dermatitis pathophysiology and addressing only mast cells does not match the comprehensive pharmaceutical approach; (6) cross-check brand claims — brands marketing therapeutic-tier allergy benefit from quercetin inclusion at typical pet food rates without bioavailability enhancement are misrepresenting expected effect magnitude.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate quercetin inclusion per our published methodology, since pet food inclusion rates are typically sub-therapeutic and the bioavailability limit on free quercetin makes pet food inclusion functionally below therapeutic-effect threshold. The marketing-evidence-gap framework parallels concerns documented across CLA, CoQ10, phosphatidylserine, milk thistle, ginger, turmeric, and other supplementation-framework controversy pages. Future rubric extension under consideration: brands disclosing quercetin inclusion rate with bioavailability enhancement (quercetin phytosome, EMIQ) and documented therapeutic-dose calibration would warrant scoring consideration; aggregate "with quercetin" marketing claims without bioavailability enhancement disclosure would not. For now, our recommendation: appreciate quercetin inclusion as a flavor and marketing-claim component, do not expect therapeutic allergy effect at typical pet food and supplement inclusion rates without bioavailability enhancement, and work with your veterinarian on appropriate pharmaceutical interventions for diagnosed atopic dermatitis or allergy concerns.